Kisspeptin Peptide: What It Is and How It Works
Kisspeptin is a natural hormone made in the brain that acts as a key switch in the chain of signals behind puberty and fertility. The FDA has approved no kisspeptin medicine, and none appears in the EU's central medicines data, so it is still an investigational hormone.
The story is odd. The gene was first found in 1996 because it held back the spread of skin cancer cells in the lab. Only in 2003 did scientists learn that people without a working kisspeptin receptor do not go through puberty normally. This page walks through the discovery, how the signal chain works, what small human studies measured, where the evidence is thin and what the regulators say. It gives no amounts, schedules or advice on use.
On this page
Key facts
Plain definition: A family of short peptides cut from one protein, made in the hypothalamus. Kisspeptin-54 is the main form in human blood.
What it does: It switches on GnRH release, which drives the pituitary hormones LH and FSH, which tell the testes and ovaries to make sex hormones.
What studies show: Short hormone rises in small, supervised trials. The response fades with repeated exposure.
What it is not: Not an approved medicine. Two trials of a kisspeptin analogue in men with low testosterone stopped early.
Status on 22 November 2026: No FDA approval, and no entry in EMA's central medicines data. FDA lists kisspeptin-10 in compounding Category 2, a safety flag.
Sources: Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022; Drugs@FDA through openFDA, search for kisspeptin; FDA, bulk drug substances that may present significant safety risks (Category 2); ClinicalTrials.gov NCT02381288, TAK-448 in men with low testosterone
What is kisspeptin?
Kisspeptin is a hypothalamic neuropeptide: a short chain of amino acids that nerve cells in the hypothalamus release as a signal. Reviewers describe it as acting through the hypothalamus to switch on gonadotropin-releasing hormone, or GnRH, and the pituitary hormones that follow it.
One gene, several pieces. The KISS1 gene makes a protein of 145 amino acids. The body cuts it into shorter pieces. The 54-unit piece was first called metastin, and shorter ones of 14, 13 and 10 units also exist. Together they are the kisspeptins. A 2009 review says it is still unclear how the short ones are cut from the large one.
So it is a family, not one molecule. Kisspeptin-54 is the main product of the gene and the major form circulating in human blood. Kisspeptin-10 is the short form that FDA staff reviewed in 2024. When someone says kisspeptin, ask which piece they mean.
The name. KiSS-1 is widely said to nod to Hershey's Kisses, the chocolate made in Hershey, Pennsylvania, where the gene was found, with SS also read as suppressor sequence. No source we opened quotes the discoverers themselves, and one peer-reviewed review hedges that it "may have been named with a bit of whimsy".
Sources: Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022; Gottsch and colleagues, From KISS1 to kisspeptins, Peptides 2009 review; Xie and colleagues, kisspeptin and the reproductive axis, Front Endocrinol 2022 review; Jayasena and colleagues, IVF, J Clin Invest 2014; FDA evaluation of kisspeptin-10, 5 July 2024; University of Bristol, Molecule of the Month: kisspeptin
How was kisspeptin discovered?
Kisspeptin was discovered in 1996 as a gene, not a hormone. Researchers at Penn State's medical college in Hershey found KiSS-1 in melanoma cells that had lost their power to spread. Adding a full copy of the gene to melanoma cells cut their spread in the lab in step with how active the gene was, while tumors still formed. The authors said this strongly suggested a suppressor role. It was cell and animal work, not a human treatment.
| When | What happened |
|---|---|
| 1996 | The KISS1 gene is found in melanoma cells by a team at Penn State in Hershey. In the lab, adding it to skin cancer cells cut their ability to spread. It was not yet linked to puberty. |
| 2001 | Two teams isolate peptides made from the gene in human placenta. One names the 54-unit peptide metastin. The other names its pieces kisspeptins. The receptor, later called GPR54, is shown to be switched on by them. |
| 2003 | French and American teams report that people with a broken GPR54 gene do not go through puberty normally, and mice without it also fail to mature. Reproduction scientists take notice, seven years after the gene was found. |
| 2005 to 2009 | Imperial College London gives kisspeptin-54 to healthy men and women, then to women whose periods stopped. Hormones rise, but with repeated exposure the response shrinks. |
| 2014 to 2015 | Early IVF studies use kisspeptin-54 to trigger egg maturation, with no comparison group. |
| 2017 to 2023 | Brain scan trials in healthy men, then in women and men with low sexual desire, report changes in brain responses versus placebo. |
| 2023 to 2026 | Two Takeda trials of a kisspeptin analogue stop early. The FDA lists kisspeptin-10 in compounding Category 2 and its advisers vote 11 to 0 against putting it on the bulks list. New Phase 2 trials recruit. |
2001, two names for one family. A Takeda team reported a 54-amino-acid peptide from human placenta and called it metastin. A second group isolated 54-, 14- and 13-unit peptides from the same gene and called them kisspeptins. In the 1996 blot the gene was most active in the placenta among normal tissues tested, and a 2001 paper found the gene highly active in brain and placenta. The receptor, first an orphan with no known partner, was shown to be switched on by these peptides and to be most active in brain, pituitary and placenta.
2003, the turn to reproduction. A French team studied a family of five siblings whose puberty did not mature normally and found each carried the same deletion in the GPR54 gene. Later that year a Boston-led team reported GPR54 mutations in people and showed that mice without the receptor also fail to mature sexually. A 2009 review notes that reproduction scientists only took notice in 2003, seven years after the gene was found.
Sources: Lee and colleagues, KiSS-1, J Natl Cancer Inst 1996; Ohtaki and colleagues, metastin, Nature 2001; Kotani and colleagues, kisspeptins, J Biol Chem 2001; Muir and colleagues, the receptor, J Biol Chem 2001; de Roux and colleagues, GPR54 deletion, PNAS 2003; Seminara and colleagues, GPR54 mutations, NEJM 2003; Gottsch and colleagues, From KISS1 to kisspeptins, Peptides 2009 review
How does kisspeptin work in the body?
Kisspeptin works by switching on GnRH. Puberty starts when the hypothalamus begins to release GnRH. Kisspeptin acts on the hypothalamus to start that release, and GnRH then drives the pituitary to release LH and FSH. Those two hormones tell the testes to make testosterone in men and the ovaries to make estradiol in women. Kisspeptin therefore acts several steps above the sex hormones.
- Hypothalamus: kisspeptin nerve cells release kisspeptin.
- GnRH cells: kisspeptin binds the receptor GPR54 (KISS1R) on them and they release GnRH.
- Pituitary: GnRH prompts the release of LH and FSH.
- Testes and ovaries: LH and FSH prompt testosterone or estradiol.
The mouse clue. Mice without GPR54 had reproductive organs that failed to mature, yet they still answered GnRH and gonadotropins. That fits kisspeptin sitting upstream of GnRH, not replacing it. This is mouse data.
Estrogen feedback. Kisspeptin nerve cells in an area called the arcuate nucleus also carry neurokinin B and dynorphin and are known as KNDy neurons. A review says they take part in both the brake and the boost that estrogen applies to GnRH. In the human preoptic area, kisspeptin cells also handle the boost.
Switch, not trigger. Kisspeptin is a key switch in the chain. One review concludes it is more likely an amplifier of GnRH signals than the single trigger of puberty, because other partners help time it. The same review still calls it a key factor in starting puberty. A broken receptor in people alone does not show that kisspeptin "causes" puberty.
Pregnancy. The placenta makes kisspeptin, and one review says blood levels of kisspeptin-54 rise a lot through pregnancy. We did not open the studies behind that line.
Sources: Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022; Seminara and colleagues, GPR54 mutations, NEJM 2003; Xie and colleagues, kisspeptin and the reproductive axis, Front Endocrinol 2022 review; University of Bristol, Molecule of the Month: kisspeptin; Dhillo and colleagues, healthy men, JCEM 2005
What have human studies of kisspeptin found?
Human studies of kisspeptin found short rises in reproductive hormones, early IVF results and shifts in brain scan responses, all in small, supervised groups. Most came from one London research group. The table gives who was studied, what was measured and what came out, in plain words. It leaves out how, how much and how often kisspeptin was given, on purpose.
| Year | Who | What was measured | What it showed |
|---|---|---|---|
| 2005 | Healthy men | LH, FSH and testosterone after kisspeptin-54 versus saline | All three rose for a short time. Testosterone moved only a little. |
| 2007 | Healthy women | LH across the menstrual cycle | LH rose in every phase. The effect was biggest just before ovulation and smallest early in the cycle. Very small groups. |
| 2009 | Five women per group with hypothalamic amenorrhea | Hormone response to repeated kisspeptin versus saline | Strong at first, then fading with repeated exposure. The pituitary still answered GnRH. |
| 2014 | 53 women having IVF | Egg maturation, embryo transfer and pregnancy | Eggs matured. 92% had embryos transferred, 40% had a biochemical and 23% a clinical pregnancy. Early exploratory study with no comparison group, so not proof of effect. |
| 2015 | 60 IVF patients at high risk of OHSS | Egg maturation and OHSS | Eggs matured in 95%. No woman had moderate, severe or critical OHSS. Open-label, no placebo. |
| 2017 | 29 healthy young men | Brain scan responses to images | More limbic (emotion and reward) activity for sexual and couple-bonding images than with vehicle. |
| 2022 | 40 randomized women with low sexual desire (HSDD) | Brain scan responses; 32 finished both visits | Brain responses to erotic and face images shifted. This was not a trial of symptom relief. |
| 2023 | 37 randomized men with HSDD | Brain scan responses; 32 finished | Brain activity changed versus placebo. Secondary results included more penile tumescence to sexual videos and more happiness about sex. Hope for future work, not proof. |
Low sexual desire. The 2022 trial in women and the 2023 trial in men were double-blind, placebo-controlled crossover studies. Their main outcome was brain scan response, not a desire score. The authors of the men's paper wrote of potential as a first drug treatment, which is hope, not proof, and they described the condition as affecting 8% of men without tracing that number. No replication has turned up in our sources. Our page on peptides and libido covers the wider topic of drugs people ask about for desire.
A lab-made relative. MVT-602 is a longer-acting kisspeptin receptor agonist, an analogue and not natural kisspeptin. In nine healthy women its LH peak came later than with kisspeptin-54 and stayed up longer. Two later placebo-controlled trials in healthy women reported it safe and well tolerated. Those were short studies linked to the company developing it.
The analogue that missed. Takeda tested a kisspeptin-based drug called TAK-448 in men with low testosterone. One 17-man Phase 2a trial was stopped because it did not meet its primary endpoint, and a second trial in 15 overweight or obese men with hypogonadotropic hypogonadism was also stopped for missing its primary goal.
Who wrote the evidence. Two Imperial authors have consulted for Myovant Sciences, a company developing a kisspeptin receptor agonist. That is a relevant interest to note when this group is the main source of human data.
Sources: Dhillo and colleagues, healthy men, JCEM 2005; Dhillo and colleagues, healthy women, JCEM 2007; Jayasena and colleagues, hypothalamic amenorrhea, JCEM 2009; Jayasena and colleagues, IVF, J Clin Invest 2014; Abbara and colleagues, women at risk of OHSS, JCEM 2015; Comninos and colleagues, brain imaging, J Clin Invest 2017; Comninos and colleagues, JCI Insight 2018; Thurston and colleagues, women with HSDD, JAMA Netw Open 2022; Mills and colleagues, men with HSDD, JAMA Netw Open 2023; Abbara and colleagues, MVT-602, J Clin Invest 2020; Abbara and colleagues, MVT-602 safety, Fertil Steril 2024; ClinicalTrials.gov NCT02381288, TAK-448 in men with low testosterone; ClinicalTrials.gov NCT02369796, TAK-448 in men with hypogonadotropic hypogonadism; Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022
Why does the kisspeptin response fade?
The response fades because repeated exposure makes the body answer less. The word is tachyphylaxis. In the 2009 trial in women with hypothalamic amenorrhea the hormone response was strong at first and then shrank, which the authors called desensitization. Imperial authors list it, with a short duration of action, among the development challenges for natural kisspeptin forms.
The pituitary still worked. After kisspeptin exposure the women still answered GnRH, which suggests the pituitary itself was fine when the kisspeptin response faded. A 2013 study in healthy women found their cycles continued, though they ran slightly shorter, in a tiny study.
An open question, August 2026. The Imperial group published a study in 15 healthy men to find a way to give kisspeptin-10 so the response lasts. The authors report a sustained response under one pattern and not another. We leave the patterns out. It is a tiny, early study in healthy men.
Sources: Jayasena and colleagues, hypothalamic amenorrhea, JCEM 2009; Jayasena and colleagues, healthy women, JCEM 2013; Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022; Yeung and colleagues, Eur J Endocrinol 2026
Is kisspeptin safe?
Nobody can say yet. Published human studies mostly reported no side effects: the men's trial reported none, with no significant change in blood pressure or heart rate, and the 2010 amenorrhea study also reported no adverse effects. Those studies were small, short and supervised, so rare and long-term effects are unknown.
What FDA staff wrote. In July 2024 FDA reviewers wrote that short-term kisspeptin-10 had not raised major safety concerns in studies to date, but they found no studies that assessed adverse events in the context of treating disease in men. The two sentences belong together. They also flagged a lack of information on immunogenicity, the risk of an immune reaction, and said kisspeptin-10 is not well characterized from a physical and chemical view.
Limits on who was studied. The men's trial included only right-handed heterosexual men, and its authors say whether the findings apply to a wider population remains to be determined.
Sources: Mills and colleagues, full text, PMC; Jayasena and colleagues, Clin Pharmacol Ther 2010; FDA evaluation of kisspeptin-10, 5 July 2024; FDA, bulk drug substances that may present significant safety risks (Category 2)
Is kisspeptin FDA approved?
No. The FDA has not approved any kisspeptin medicine, and no EU-authorized kisspeptin medicine appears in EMA's data. FDA places kisspeptin-10 in "Category 2" of bulk substances for compounding, which means the agency flagged possible significant safety risks. Category 2 is a safety flag, not an approval and not a ban.
| Question | Answer |
|---|---|
| FDA approval | No kisspeptin medicine. The openFDA search for kisspeptin returned no matches on 22 November 2026, and FDA staff wrote that kisspeptin-10 is not a component of an FDA-approved drug. |
| EU (EMA) authorization | No entry for kisspeptin, metastin or KISS1 in EMA’s central medicines data of 21 November 2026. National approvals were not searched. |
| FDA compounding list | Kisspeptin-10 sits in Category 2 under section 503A, added 29 September 2023. That is a safety flag, not an approval and not a ban. |
| FDA advisers | On 29 October 2024 the advisory committee voted 11 to 0 that kisspeptin-10 should not go on the 503A bulks list. A vote is advice. We found no final rule. |
| Research now | Two Phase 2 trials at Massachusetts General Hospital were recruiting on 22 November 2026: one in idiopathic hypogonadotropic hypogonadism, one in hypothalamic amenorrhea. |
| Sport | The 2026 WADA list text, as copied by a German sports university, names kisspeptin and its agonist analogues in S2 within the testosterone-stimulating peptides for males. |
Why the advisers said no. FDA staff said the evidence on effectiveness for men with secondary hypogonadism is insufficient, that immunogenicity risk is unknown and that approved drugs already exist for that condition. They concluded the criteria weigh against listing it. The nomination had come from a pharmacy network for male hypogonadism. The FDA row for kisspeptin-10 warns of a possible immune reaction, and says the agency has little safety information on the ways of giving it that were proposed.
Research labels. FDA warning letters to online peptide sellers, for example one dated 24 August 2026, say that "research use only" labels do not change a product's intended use when a website shows human-use claims. That letter does not mention kisspeptin. No source we opened tests products sold online as kisspeptin, so this page does not say they match the studied material or are as safe.
We state status lines against primary records, as our medical review policy describes. One thing we could not confirm is what FDA decided after the October 2024 vote.
Sources: Drugs@FDA through openFDA, search for kisspeptin; EMA medicines data file, 2,765 records; FDA, bulk drug substances that may present significant safety risks (Category 2); FDA evaluation of kisspeptin-10, 5 July 2024; FDA Pharmacy Compounding Advisory Committee minutes, 29 October 2024; ClinicalTrials.gov NCT05896293, kisspeptin in idiopathic hypogonadotropic hypogonadism; ClinicalTrials.gov NCT07224438, kisspeptin in hypothalamic amenorrhea; German Sport University Cologne, S2 peptide hormones (2026 list text); FDA warning letter 735067, 24 August 2026
Kisspeptin claims you may see, and what the evidence shows
Online pages about kisspeptin often say more than the studies do. This table sets six common claims next to the sources we read. It is the part most pages skip.
| Claim | What the sources show |
|---|---|
| Kisspeptin raises testosterone. | A short rise in healthy men in 2005. Two Takeda trials of a kisspeptin analogue in men with low testosterone were stopped for missing their main goal, and FDA staff found too little evidence of effectiveness. |
| Kisspeptin treats low sex drive. | The 2022 and 2023 trials measured brain responses and short lab measures in small groups. No trial shows relief of symptoms over time. |
| Kisspeptin boosts fertility. | It triggered egg maturation in early IVF studies with no comparison group. That is a narrow, supervised use, not a general fertility effect. |
| Kisspeptin is proven safe. | Small, short, supervised studies mostly reported no side effects. Long-term safety is unknown, and FDA staff found no studies of adverse events in men being treated for disease. |
| Kisspeptin works the same way for as long as you use it. | Repeated exposure made the hormone response fade in several studies. Researchers call this tachyphylaxis. |
| A “research use only” product is the same material the trials used. | No source we opened tests such products. FDA says research labels do not change a product’s intended use when a seller’s site shows human-use claims. |
Readers comparing hormone topics will also find our guide to peptides and testosterone, which ranks several options by their evidence.
Sources: Dhillo and colleagues, healthy men, JCEM 2005; ClinicalTrials.gov NCT02381288, TAK-448 in men with low testosterone; ClinicalTrials.gov NCT02369796, TAK-448 in men with hypogonadotropic hypogonadism; FDA evaluation of kisspeptin-10, 5 July 2024; Thurston and colleagues, women with HSDD, JAMA Netw Open 2022; Mills and colleagues, men with HSDD, JAMA Netw Open 2023; Jayasena and colleagues, IVF, J Clin Invest 2014; Jayasena and colleagues, hypothalamic amenorrhea, JCEM 2009; Mills and colleagues, full text, PMC; FDA warning letter 735067, 24 August 2026
How is kisspeptin different from gonadorelin and hCG?
Kisspeptin, gonadorelin and hCG are three different things on one hormone ladder, and they are not interchangeable. Kisspeptin acts above GnRH. Gonadorelin is the lab name for GnRH itself, one step below. hCG is a separate, older drug that acts like LH.
Gonadorelin. In FDA's approved-drug data its only US brand names, Factrel and Lutrepulse, are listed as discontinued, so it is not a current approved product either. Compounded gonadorelin is a separate matter we did not research. Our gonadorelin page covers its own record.
hCG. Its FDA label lists use in selected cases of hypogonadotropic hypogonadism in males. Kisspeptin has no such approval. For the hCG record, see our hCG page. The 2026 WADA list text names GnRH and gonadorelin in the same male group as kisspeptin.
Sources: Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022; Drugs@FDA through openFDA, gonadorelin; Chorionic gonadotropin labels via openFDA; German Sport University Cologne, S2 peptide hormones (2026 list text)
What else do people ask about kisspeptin?
What is kisspeptin?+
Kisspeptin is a hormone made in the hypothalamus, a control area at the base of the brain. It tells GnRH cells to start signalling, which sets off the pituitary hormones LH and FSH and, through them, the testes and ovaries. It is a family of pieces cut from one protein.
Is kisspeptin a peptide?+
Yes. Kisspeptin counts as a peptide because it is built from amino acids joined in a short chain. The KISS1 gene makes a 145-unit protein, and the body cuts it into pieces of 54, 14, 13 and 10 units, called kisspeptins together.
What is kisspeptin-10?+
Kisspeptin-10 is the shortest of the pieces, 10 amino acids long. It is the form FDA staff reviewed in 2024. FDA lists it in Category 2 for compounding, a safety flag. Kisspeptin-54 is the main form in human blood.
How does kisspeptin work?+
It binds a receptor, GPR54 (also called KISS1R), on GnRH nerve cells. That switches on GnRH release, which drives LH and FSH, which tell the testes and ovaries to make testosterone or estradiol. It sits several steps above the sex hormones.
Is kisspeptin FDA approved?+
No. The FDA has approved no kisspeptin medicine, and no EU-authorized kisspeptin medicine appears in EMA’s central data. It is still an investigational hormone studied in small trials.
What are the benefits of kisspeptin?+
No benefit is established for any use. Trials measured hormone levels, egg maturation and brain scan responses in small groups. Measuring a response is not the same as showing a person feels or functions better.
What are the side effects of kisspeptin?+
Several small, supervised human studies reported no side effects or adverse events. They were short, so rare and long-term effects are unknown. FDA also flags a possible immune reaction risk for compounded kisspeptin-10.
What does kisspeptin do for women?+
Studies in women looked at the menstrual cycle, a stopped-period condition called hypothalamic amenorrhea, egg maturation in IVF and brain responses in low sexual desire. Each was small, and none made kisspeptin an approved treatment.
What does kisspeptin do for men?+
In healthy men a short exposure raised LH, FSH and testosterone for a time. Brain scan studies followed in men with low sexual desire. Trials of a kisspeptin analogue in men with low testosterone were stopped for missing their main goal.
Does kisspeptin raise testosterone?+
Briefly, in healthy men in one early study. That is not the same as treating low testosterone. Two analogue trials in men with low testosterone ended early, and FDA staff found insufficient evidence of effectiveness for men with secondary hypogonadism.
Is kisspeptin the same as gonadorelin or hCG?+
No. Gonadorelin is the lab name for GnRH, the hormone one step below kisspeptin. hCG is a separate, older approved drug. FDA lists hCG for selected cases of male hypogonadotropic hypogonadism and kisspeptin has no such approval.
Does kisspeptin help fertility?+
In early IVF studies it triggered egg maturation. Those studies had no comparison group and tested small numbers, so they do not show that kisspeptin improves fertility in general.
Why is it called kisspeptin?+
The gene name KiSS-1 is widely said to nod to Hershey’s Kisses, the chocolate made in Hershey, Pennsylvania, where the gene was found. One peer-reviewed review says it may have been named with a bit of whimsy.
Is kisspeptin banned in sport?+
A secondary copy of the 2026 WADA list places kisspeptin and its agonist analogues in S2 for males, within the testosterone-stimulating peptides. We could not open WADA’s own file, so athletes should check it directly.
Sources: Tsoutsouki, Abbara, Dhillo, Curr Opin Pharmacol 2022; Gottsch and colleagues, From KISS1 to kisspeptins, Peptides 2009 review; Drugs@FDA through openFDA, search for kisspeptin; FDA, bulk drug substances that may present significant safety risks (Category 2); FDA evaluation of kisspeptin-10, 5 July 2024; Chorionic gonadotropin labels via openFDA; German Sport University Cologne, S2 peptide hormones (2026 list text)
What did we learn about kisspeptin?
In short, kisspeptin went from a cancer-spread suppressor in 1996 to a key switch for GnRH, puberty and fertility in 2003, yet it is still an investigational hormone with small trials, a fading response and no approved medicine.
The kisspeptin lesson sits in a channel series that explains how hormones and peptide drugs work and lists its sources. It recommends nothing. Two other hormone drugs covered in the series are octreotide and lanreotide.
Found a mistake in what we wrote on kisspeptin? Tell us through the corrections policy.
Sources: Lee and colleagues, KiSS-1, J Natl Cancer Inst 1996; de Roux and colleagues, GPR54 deletion, PNAS 2003; Drugs@FDA through openFDA, search for kisspeptin; FDA, bulk drug substances that may present significant safety risks (Category 2)
This is education, not medical advice. Everything here comes from published studies, FDA records and trial registries about kisspeptin, which is not an approved medicine. Whether a hormone treatment suits someone is for them to settle with their own doctor.